Latest News

(UroToday.com) Prostate-specific membrane antigen (PSMA) is selectively overexpressed in most advanced prostate cancer tumors with limited expression in other organs (including celery and lacrimal glands, renal tubules, and small intestines). Sequential prospective clinical trials of anti-PSMA mAb J591 and small molecule PSMA-617 radiolabelled with the beta emitter 177 LU, demonstrated tolerability with accurate targeting in […]

Percutaneous nephrolithotomy is the standard surgical management of large renal calculi. Percutaneous renal access using the triangulation method has been an enigma for the endourologist to master and teach. This surgical conundrum is due to the uncertainty in the angle and depth required to puncture the target calyx. We describe a novel trigonometric method of […]

(UroToday.com) The CARD study (Figure 1) was a multicenter, randomized, open-label study enrolling patients with metastatic castrate-resistant prostate cancer who progressed in less than 12 months on prior androgen receptor-targeted agent1 (before or after docetaxel therapy).

(UroToday.com) Androgen deprivation therapy (ADT) is the mainstay of treatment for advanced prostate cancer. In recent years there has been a rapid increase in therapeutic options for advanced cancers. Many drugs have been approved for the same setting (docetaxel, enzalutamide, abiraterone, darolutamide, apalutamide, and olaparib). Despite the plethora of drugs that have been approved, there […]

BACKGROUND Testicular mixed germ cell tumors (GCTs) represent a spectrum of malignancies that differ in terms of histopathology, clinical complications, and overall outcome. A variety of aggressive combinations containing different histological types have been described among such testicular tumors.

The role of lymph node dissection (LND) is still controversial for upper tract urothelial carcinoma (UTUC), and there are no guidelines regarding its use. This study was conducted to find a higher level of evidence for the survival benefits based on the number of LNs removed during radical nephroureterectomy (RNUx) through a systematic review and […]

ADONIS is an ongoing observational study in 9 European countries, designed to evaluate treatment patterns/outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib and/or second-line axitinib post sunitinib.

The burden of renal cell carcinoma (RCC) in young adults received marginal attention. We assessed contemporary gender, race and stage-specific incidence and trends of RCC among young adults (20-39 years-old) in the United States.

Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity.

In this study using national health insurance data, we investigated the risk of ischemic heart disease (IHD) and stroke among prostate cancer (PC) survivors compared with the general population, as well as the risk of cardiovascular disease (CVD) according to primary treatment.